Forbion is a Naarden, Netherlands-based venture capital firm. Value Add VC tracks 4 companies Forbion has invested in and 5 venture rounds it took part in (3 as lead).
Forbion key facts (as of )
| Fact | Value | Source |
|---|---|---|
| Headquarters | Naarden, Netherlands | SEC Form ADV (IAPD), September 16, 2026 |
| Type | Venture capital firm | Value Add VC classification |
| Funds tracked | 1 | Funds table on this page (each fund cites its source) |
| Venture rounds tracked | 5 (led 3, joined 2) 4 in the last 12 months | Recent deals table on this page (each round cites its source) |
| Portfolio companies tracked | 4 | Portfolio list on this page |
Recent deals we track
5Track record: led 3 and participated in 2 of 5 tracked venture rounds · 4 in the last 12 months · led 2 Series C, 1 Series B
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | OMass Therapeutics | Series C | Led | $310M | — | Bain Capital Life SciencesLeadunverifiedForbionLeadunverifiedGoogle Ventures (GV)unverifiedNorthpond VenturesunverifiedSanofi VenturesunverifiedBritish Business BankunverifiedJanus Henderson InvestorsunverifiedNovo HoldingsSynconaOxford Science EnterprisesSV Health Investors+2 more | ValueSpectrum |
| Sep 16, 2026 | Sling Therapeutics | Series C | Led | $123M | — | Pulse story | |
| Sep 9, 2026 | Solstice Oncology | Series A | Participated | $225M | — | GlobeNewswire | |
| Nov 5, 2025 | Braveheart Bio | Series A | Participated | $185M | — | PR Newswire | |
| Sling Therapeutics | Series B | Led | $123M | — | Fierce Biotech |
Is this your firm? Get featured or correct your listing →
We track Forbion but have little verified detail yet.
At a glance
Forbion appears in 5 funding rounds tracked by ValueAddVC since 2025, leading 3. Its most frequent sector in these rounds is Health & Biotech, and its most recent tracked deal was OMass Therapeutics' $310M Series C round (Oct 15, 2026). It co-invests most often with Sectoral Asset Management and TPG. ValueAddVC also tracks 1 fund managed by Forbion.
Strategy
Recent changes
- Oct 15, 2026Oct 15, 2026Invested in OMass Therapeutics (Series C, $310M) ValueSpectrum
- Sep 16, 2026Sep 16, 2026Invested in Sling Therapeutics (Series C, $123M) BioSpace
- Sep 9, 2026Sep 9, 2026Invested in Solstice Oncology (Series A, $225M) GlobeNewswire
- Nov 5, 2025Nov 5, 2025Invested in Braveheart Bio (Series A, $185M) PR Newswire
- Jan 1, 2014Jan 1, 2014New fund: Forbion Fund ($116M) Value Add VC funds tracker
Funds
1| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| Forbion Fund | 2014 | $116M | Flagship | As of 2014Value Add VC funds tracker |
Portfolio
4 totalSector / Stage Activity
Co-Investors
8Latest Pulse
Forbion FAQ
What stage does Forbion invest at?
In the rounds Value Add VC tracks, Forbion's deals were most often Series C (2), Series A (2) and Series B (1); it led 2 Series C and 1 Series B.
What companies has Forbion backed?
Companies Value Add VC tracks as Forbion investments include OMass Therapeutics, Sling Therapeutics, Solstice Oncology and Braveheart Bio.
Where is Forbion based?
Forbion is headquartered in Naarden, Netherlands, according to SEC Form ADV (IAPD).
Who does Forbion co-invest with most?
In the rounds Value Add tracks, Forbion most often invests alongside Andreessen Horowitz (1 shared deal), Frazier Life Sciences (1 shared deal), Google Ventures (GV) (1 shared deal), Janus Henderson Investors (1 shared deal), OrbiMed Advisors (1 shared deal).
Sources & methodologyshow
- GlobeNewswireprimary source1 fact
- PR Newswireprimary source1 fact
- Fierce Biotechmajor outlet1 fact
- BioSpaceresearch database1 fact
- Value Add VC funds trackerValue Add VC data1 fact
- ValueSpectrumValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.